|By PR Newswire||
|March 7, 2014 08:01 AM EST||
NEW YORK, March 7, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts Review released its analysts' notes regarding MDU Resources Group Inc. (NYSE: MDU), UGI Corp. (NYSE: UGI), Vectren Corporation (NYSE: VVC), ALLETE, Inc. (NYSE: ALE), and Avista Corp. (NYSE: AVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
MDU Resources Group Inc. Analyst Notes
On March 4, 2014, MDU Resources Group Inc.'s (MDU Resources) stock increased 1.04%, ending the day at $33.90. Over the previous three trading sessions, shares of MDU Resources declined 0.59%, compared to the Dow Jones Industrial Average which advanced 0.76% during the same period. The full analyst notes on MDU Resources Group Inc. are available to download free of charge at:
UGI Corp. Analyst Notes
On March 4, 2014, UGI Corp.'s (UGI) stock increased 0.84%, ending the day at $44.67. Over the previous three trading sessions, shares of UGI increased 0.70%, compared to the Dow Jones Industrial Average which gained 0.76% during the same period. The full analyst notes on UGI Corp. are available to download free of charge at:
Vectren Corporation Analyst Notes
On February 19, 2014, Vectren Corporation (Vectren) reported its financial results for Q4 2013 and full year 2013. The Company reported annual consolidated net income of $136.6 million, or $1.66 per diluted share, versus net income of $159.0 million, or $1.94 per diluted share in full year 2012. According to the Company, Utility Group earnings were $141.8 million in full year 2013, versus $138.0 million in full year 2012; while Nonutility Group earnings were $33.0 million in full year 2013, (not including the results of ProLiance), versus earnings of $21.7 million in full year 2012. Q4 2013 consolidated net income was $49.8 million, or $0.60 per diluted share, versus net income of $42.8 million, or $0.52 per diluted share, in Q4 2012. Full year 2013 operating revenues were reported to be $2.5 billion, up 11.6% YoY; while quarterly revenues increased 5.6% YoY to $680.0 million. The Company stated that for full year 2014, it anticipates consolidated earnings of $2.15 to $2.35 per share. The full analyst notes on Vectren Corporation are available to download free of charge at:
ALLETE, Inc. Analyst Notes
On February 26, 2014, ALLETE, Inc. (ALLETE) announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at $49.75 per share in connection with the forward sale agreement. The Company informed that the size of the offering was increased from the previously announced 2.5 million shares. ALLETE stated that together with this offering, the underwriters have been granted an option to purchase an additional 420,000 shares of the Company's common stock solely to cover over-allotments, if any. The Company added that it plans to use net proceeds from settlement of the forward sale agreement or upon issuance and sale to the underwriters of shares for corporate purposes, including capital investments. ALLETE informed that J.P. Morgan and Baird are acting as joint book-running managers for the offering, and RBC Capital Markets and Wells Fargo Securities are acting as co-managers for the offering. The Company further stated that it entered into a forward sale agreement in connection with the offering with an affiliate of J.P. Morgan (the Counterparty) under which the Company agrees to sell to the Counterparty the same number of shares of the Company's common stock sold by an affiliate of the Counterparty to the underwriters for sale in the underwritten public offering. The full analyst notes on ALLETE, Inc. are available to download free of charge at:
Avista Corp. Analyst Notes
On February 26, 2014, Avista Corp. (Avista) reported its financial results for Q4 2013 and full year 2013.
The Company declared net income attributable to Avista shareholders of $111.1 million, or $1.85 per diluted share, for full year 2013, versus $78.2 million, or $1.32 per diluted share, for full year 2012. For Q4 2013, net income attributable to Avista shareholders was $31.7 million, or $0.53 per diluted share, versus $15.9 million, or $0.26 per diluted share, for Q4 2012. Full-year 2013 operating revenues increased 4.6% YoY to $1.6 billion, while quarterly operating revenues grew to $447.7 million, up 9.0% YoY. Avista Chairman, President and CEO Scott Morris, commented, "We had a very good year in 2013, with utility earnings above our expectations, and significant improvement at Ecova as compared to 2012." He added, "Lastly, we are confirming our 2014 earnings guidance with a consolidated range of $1.77 to $1.97 per diluted share. This excludes any impact from the planned acquisition of AERC." The full analyst notes on Avista Corp. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review